Abstract

This Viewpoint discusses laws mandating insurance coverage of biomarker testing to broaden access to care for patients with cancer.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Physician behavior and perceptions around genetic biomarker test utilization for the management of newly diagnosed advanced ovarian cancer patients: US physician survey (223)
Ozan Ozgoren ... Gráinne Long
Gynecologic Oncology | VOL. 166
Ozan Ozgoren, et. al.Ozan Ozgoren ... Gráinne Long
01 Aug 2022
State legislative trends related to biomarker testing.
Ruth C Carlos ... Robert A Smith
Cancer | VOL. 128
Ruth C Carlos, et. al.Ruth C Carlos ... Robert A Smith
24 May 2022
P60.14 A United States Study Focused on Patients’ Understanding of, Attitudes Towards, and Barriers to the Use of Biomarker Testing for NSCLC
J Schrag ... M Molina
Journal of Thoracic Oncology | VOL. 16
J Schrag, et. al.J Schrag ... M Molina
01 Oct 2021
Reducing roadblocks to employee health care through benefit design implications and unintended consequences of utilization management in cancer treatment
Patricia J Goldsmith
Strategic HR Review | VOL. 22
Patricia J GoldsmithPatricia J Goldsmith
11 Jul 2023
View more papers

More From: JAMA

Paper Title
Journal
Date
Author
Audio Highlights.
-
JAMA | VOL. 331
--
21 May 2024
JAMA.
-
JAMA | VOL. 331
--
21 May 2024
Survival Benefit Associated With Participation in Clinical Trials of Anticancer Drugs: A Systematic Review and Meta-analysis.
Renata Iskander ... Jonathan Kimmelman
JAMA | VOL. -
Renata Iskander, et. al.Renata Iskander ... Jonathan Kimmelman
20 May 2024
Federal Trade Commission Oversight of the Pharmaceutical Industry.
Amy Kapczynski Jd
JAMA | VOL. -
Amy Kapczynski JdAmy Kapczynski Jd
20 May 2024
View more papers